Related references
Note: Only part of the references are listed.R453Plus1Toolbox: an R/Bioconductor package for analyzing Roche 454 Sequencing data
Hans-Ulrich Klein et al.
BIOINFORMATICS (2011)
Strategy for Robust Detection of Insertions, Deletions, and Point Mutations in CEBPA, a GC-Rich Content Gene, Using 454 Next-Generation Deep-Sequencing Technology
Vera Grossmann et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2011)
Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance
V. Grossmann et al.
LEUKEMIA (2011)
A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases
V. Grossmann et al.
LEUKEMIA (2011)
Database resources of the National Center for Biotechnology Information
Eric W. Sayers et al.
NUCLEIC ACIDS RESEARCH (2011)
A multi-site study using high-resolution HLA genotyping by next generation sequencing
C. L. Holcomb et al.
TISSUE ANTIGENS (2011)
Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value
Alexander E. Smith et al.
BLOOD (2010)
Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1
Alexander Kohlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
TP53 Mutation and Survival in Chronic Lymphocytic Leukemia
Thorsten Zenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Next Generation Sequencing for Clinical Diagnostics-Principles and Application to Targeted Resequencing for Hypertrophic Cardiomyopathy A Paper from the 2009 William Beaumont Hospital Symposium on Molecular Pathology
Karl V. Voelkerding et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2010)
APPLICATIONS OF NEXT-GENERATION SEQUENCING Sequencing technologies - the next generation
Michael L. Metzker
NATURE REVIEWS GENETICS (2010)
Low-Abundance Drug-Resistant Viral Variants in Chronically HIV-Infected, Antiretroviral Treatment-Naive Patients Significantly Impact Treatment Outcomes
Birgitte B. Simen et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Mutation in TET2 in Myeloid Cancers
Francois Delhommeau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
High-resolution, high-throughput HLA genotyping by next-generation sequencing
G. Bentley et al.
TISSUE ANTIGENS (2009)
250K Single Nucleotide Polymorphism Array Karyotyping Identifies Acquired Uniparental Disomy and Homozygous Mutations, Including Novel Missense Substitutions of c-Cbl, in Myeloid Malignancies
Andrew J. Dunbar et al.
CANCER RESEARCH (2008)
A PROSPECTIVE RANDOMIZED STUDY OF IMATINIB 400 MG VS 800 MG AS A FRONTLINE THERAPY IN SOKAL HIGH RISK (HR) PH-POS CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
M. Baccarani et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib
Thomas Ernst et al.
HAEMATOLOGICA (2008)
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing
Roman K. Thomas et al.
NATURE MEDICINE (2006)
Genome sequencing in microfabricated high-density picolitre reactors
M Margulies et al.
NATURE (2005)
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years
DT Bowen et al.
BLOOD (2005)
Share Paper
